SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '046'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_C_STIC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	4 / 6	LEU A 53 LYS A 76 MET A 98 MET A 133	046 A 401 ( 3.9A) 046 A 401 ( 4.7A) 046 A 401 (-3.5A) None	0.91A	2hyyC-4o2zA: 22.1	2hyyC-4o2zA: 24.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2YFB_B_ACTB501_0 (METHYL-ACCEPTING CHEMOTAXIS TRANSDUCER)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	4 / 6	ASP A 175 ARG A 217 VAL A 232 ARG A 174	046 A 401 (-4.4A) None None None	1.20A	2yfbB-4o2zA: 2.2	2yfbB-4o2zA: 21.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BJW_F_SVRF502_3 (PHOSPHOLIPASE A2)	5mzn	HELICASE SEN1,HELICASE SEN1 (Saccharomyces cerevisiae)	5 / 12	VAL A1427 LEU A1368 GLY A1369 ILE A1343 PHE A1374	None EDO A2014 (-4.2A) None None GOL A2046 ( 4.2A)	1.02A	3bjwF-5mznA: undetectable	3bjwF-5mznA: 11.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_B_NILB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	6 / 12	GLU A 94 MET A 98 LEU A 106 THR A 130 HIS A 173 ASP A 193	046 A 401 (-3.7A) 046 A 401 (-3.5A) 046 A 401 ( 4.6A) 046 A 401 (-4.0A) 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.69A	3cs9B-4o2zA: 21.3	3cs9B-4o2zA: 26.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	6 / 12	GLU A 94 MET A 98 LEU A 106 THR A 130 HIS A 173 ASP A 193	046 A 401 (-3.7A) 046 A 401 (-3.5A) 046 A 401 ( 4.6A) 046 A 401 (-4.0A) 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.67A	3cs9C-4o2zA: 21.1	3cs9C-4o2zA: 26.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	5 / 12	GLU A 94 MET A 98 LEU A 106 HIS A 173 ASP A 193	046 A 401 (-3.7A) 046 A 401 (-3.5A) 046 A 401 ( 4.6A) 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.59A	3ik3A-4o2zA: 21.6	3ik3A-4o2zA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	5 / 12	GLU A 94 MET A 98 LEU A 106 HIS A 173 ASP A 193	046 A 401 (-3.7A) 046 A 401 (-3.5A) 046 A 401 ( 4.6A) 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.63A	3ik3B-4o2zA: 21.6	3ik3B-4o2zA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IV6_D_SAMD301_0 (PUTATIVE ZN-DEPENDENT ALCOHOL DEHYDROGENASE)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	5 / 12	THR A 213 ILE A 159 ASP A 175 ARG A 174 LEU A 176	None None 046 A 401 (-4.4A) None None	1.23A	3iv6D-4o2zA: undetectable	3iv6D-4o2zA: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	6 / 12	GLU A 94 MET A 98 LEU A 106 THR A 130 HIS A 173 ASP A 193	046 A 401 (-3.7A) 046 A 401 (-3.5A) 046 A 401 ( 4.6A) 046 A 401 (-4.0A) 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.66A	3oxzA-4o2zA: 20.9	3oxzA-4o2zA: 25.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4FOR_A_FLPA711_1 (LACTOTRANSFERRIN)	5xym	50S RIBOSOMAL PROTEIN L2 (Mycolicibacteriu m smegmatis)	4 / 7	GLY C 251 VAL C 247 PRO C 249 GLY C 223	G A2466 ( 3.7A) None A A2045 ( 3.9A) C A2046 ( 3.3A)	0.83A	4forA-5xymC: undetectable	4forA-5xymC: 21.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V01_A_0LIA1776_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	6 / 12	GLU A 94 MET A 97 MET A 98 LEU A 166 HIS A 173 ASP A 193	046 A 401 (-3.7A) 046 A 401 (-3.9A) 046 A 401 (-3.5A) None 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.77A	4v01A-4o2zA: 21.3	4v01A-4o2zA: 25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	6 / 12	ALA A 61 GLU A 94 MET A 97 MET A 98 HIS A 173 ASP A 193	046 A 401 ( 4.6A) 046 A 401 (-3.7A) 046 A 401 (-3.9A) 046 A 401 (-3.5A) 046 A 401 (-4.1A) 046 A 401 (-4.3A)	1.06A	4v01B-4o2zA: 21.8	4v01B-4o2zA: 25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	6 / 12	GLU A 94 MET A 97 MET A 98 LEU A 166 HIS A 173 ASP A 193	046 A 401 (-3.7A) 046 A 401 (-3.9A) 046 A 401 (-3.5A) None 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.69A	4v01B-4o2zA: 21.8	4v01B-4o2zA: 25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V04_B_0LIB1771_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	5 / 12	ALA A 61 GLU A 94 MET A 97 HIS A 173 ASP A 193	046 A 401 ( 4.6A) 046 A 401 (-3.7A) 046 A 401 (-3.9A) 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.91A	4v04B-4o2zA: 21.8	4v04B-4o2zA: 25.94

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["2HYY_C_STIC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",4,"LEU A  53;LYS A  76;MET A  98;MET A 133","046 A 401 ( 3.9A);046 A 401 ( 4.7A);046 A 401 (-3.5A);None","0.91A","2hyyC-4o2zA:22.1",null],["2YFB_B_ACTB501_0","METHYL-ACCEPTING CHEMOTAXIS TRANSDUCER","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",4,"ASP A 175;ARG A 217;VAL A 232;ARG A 174","046 A 401 (-4.4A);None;None;None","1.20A","2yfbB-4o2zA:2.2","2hyyC-4o2zA:24.52"],["3BJW_F_SVRF502_3","PHOSPHOLIPASE A2","5mzn","HELICASE SEN1,HELICASE SEN1","Saccharomyces cerevisiae",5,"VAL A1427;LEU A1368;GLY A1369;ILE A1343;PHE A1374","None;EDO A2014 (-4.2A);None;None;GOL A2046 ( 4.2A)","1.02A","3bjwF-5mznA:undetectable","2yfbB-4o2zA:21.73"],["3CS9_B_NILB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",6,"GLU A  94;MET A  98;LEU A 106;THR A 130;HIS A 173;ASP A 193","046 A 401 (-3.7A);046 A 401 (-3.5A);046 A 401 ( 4.6A);046 A 401 (-4.0A);046 A 401 (-4.1A);046 A 401 (-4.3A)","0.69A","3cs9B-4o2zA:21.3","3bjwF-5mznA:11.08"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",6,"GLU A  94;MET A  98;LEU A 106;THR A 130;HIS A 173;ASP A 193","046 A 401 (-3.7A);046 A 401 (-3.5A);046 A 401 ( 4.6A);046 A 401 (-4.0A);046 A 401 (-4.1A);046 A 401 (-4.3A)","0.67A","3cs9C-4o2zA:21.1","3cs9B-4o2zA:26.21"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",5,"GLU A  94;MET A  98;LEU A 106;HIS A 173;ASP A 193","046 A 401 (-3.7A);046 A 401 (-3.5A);046 A 401 ( 4.6A);046 A 401 (-4.1A);046 A 401 (-4.3A)","0.59A","3ik3A-4o2zA:21.6","3cs9C-4o2zA:26.21"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",5,"GLU A  94;MET A  98;LEU A 106;HIS A 173;ASP A 193","046 A 401 (-3.7A);046 A 401 (-3.5A);046 A 401 ( 4.6A);046 A 401 (-4.1A);046 A 401 (-4.3A)","0.63A","3ik3B-4o2zA:21.6","3ik3A-4o2zA:24.93"],["3IV6_D_SAMD301_0","PUTATIVE ZN-DEPENDENT ALCOHOL DEHYDROGENASE","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",5,"THR A 213;ILE A 159;ASP A 175;ARG A 174;LEU A 176","None;None;046 A 401 (-4.4A);None;None","1.23A","3iv6D-4o2zA:undetectable","3ik3B-4o2zA:24.93"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",6,"GLU A  94;MET A  98;LEU A 106;THR A 130;HIS A 173;ASP A 193","046 A 401 (-3.7A);046 A 401 (-3.5A);046 A 401 ( 4.6A);046 A 401 (-4.0A);046 A 401 (-4.1A);046 A 401 (-4.3A)","0.66A","3oxzA-4o2zA:20.9","3iv6D-4o2zA:21.47"],["4FOR_A_FLPA711_1","LACTOTRANSFERRIN","5xym","50S RIBOSOMAL PROTEIN L2","Mycolicibacterium smegmatis",4,"GLY C 251;VAL C 247;PRO C 249;GLY C 223","  G A2466 ( 3.7A);None;  A A2045 ( 3.9A);  C A2046 ( 3.3A)","0.83A","4forA-5xymC:undetectable","3oxzA-4o2zA:25.75"],["4V01_A_0LIA1776_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",6,"GLU A  94;MET A  97;MET A  98;LEU A 166;HIS A 173;ASP A 193","046 A 401 (-3.7A);046 A 401 (-3.9A);046 A 401 (-3.5A);None;046 A 401 (-4.1A);046 A 401 (-4.3A)","0.77A","4v01A-4o2zA:21.3","4forA-5xymC:21.88"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",6,"ALA A  61;GLU A  94;MET A  97;MET A  98;HIS A 173;ASP A 193","046 A 401 ( 4.6A);046 A 401 (-3.7A);046 A 401 (-3.9A);046 A 401 (-3.5A);046 A 401 (-4.1A);046 A 401 (-4.3A)","1.06A","4v01B-4o2zA:21.8","4v01A-4o2zA:25.94"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",6,"GLU A  94;MET A  97;MET A  98;LEU A 166;HIS A 173;ASP A 193","046 A 401 (-3.7A);046 A 401 (-3.9A);046 A 401 (-3.5A);None;046 A 401 (-4.1A);046 A 401 (-4.3A)","0.69A","4v01B-4o2zA:21.8","4v01B-4o2zA:25.94"],["4V04_B_0LIB1771_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4o2z","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","Leishmania donovani",5,"ALA A  61;GLU A  94;MET A  97;HIS A 173;ASP A 193","046 A 401 ( 4.6A);046 A 401 (-3.7A);046 A 401 (-3.9A);046 A 401 (-4.1A);046 A 401 (-4.3A)","0.91A","4v04B-4o2zA:21.8","4v01B-4o2zA:25.94"]]